Clinical efficacy of gamma-oryzanol combined with Femoston for perimenopausal syndrome

Figure 1 Estradiol, luteinizing hormone, and follicle-stimulating hormone levels before and after treatment in the two groups. A: Pre- and post-treatment estradiol levels; B: Pre- and post-treatment luteinizing hormone levels; C: Pre- and post-treatment follicle-stimulating hormone levels. ^bP < 0.01, vs before treatment; ^cP < 0.05 vs control. E₂: Estradiol; LH: Luteinizing hormone; FSH: Follicle-stimulating hormone.

Figure 2 Lumbar spine (L1–4) and bilateral femoral bone mineral density before and after treatment. A: L1–4 bone mineral density before and after treatment; B: Bilateral femoral bone mineral density before and after treatment. ^bP < 0.01, vs before treatment; ^cP < 0.05 vs control.

Figure 3 Pre- and post-treatment sleeping time and frequency of awakenings from sleep in the two groups. A: Pre- and post-treatment sleeping time; B: Pre- and post-treatment frequency of awakenings from sleep. ^aP < 0.05, ^bP < 0.01, vs before treatment; ^cP < 0.05 vs control.